Oklahoma Medical Research Foundation

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1946-01-01

Employees: 501

Market Cap: -

Website: http://www.omrf.org

Clinical Trials

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

Early Phase 1

Recruiting

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: Standard of Care
Drug: Anifrolumab

First Posted Date: 2021-01-27

Last Posted Date: 2023-03-22

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 20

Registration Number: NCT04726553

Locations: 🇺🇸
Yale University Medical Center, New Haven, Connecticut, United States
🇺🇸
New York University Medical Center, New York, New York, United States
🇺🇸
Columbia Unversity Medical Center, New York, New York, United States

and more 2 locations

Antecedent Metabolic Health and Metformin Aging Study

Phase 3

Recruiting

Conditions: Chronic Disease
Insulin Resistance
Insulin Sensitivity
Mitochondria
Aging

Interventions: Drug: Placebo oral tablet
Drug: Metformin

First Posted Date: 2020-02-11

Last Posted Date: 2023-03-23

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 148

Registration Number: NCT04264897

Locations: 🇺🇸
University of Wisconsin-Madison, Madison, Wisconsin, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma Shared Clinical and Translational Resources, Oklahoma City, Oklahoma, United States

MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus Arthritis

Interventions: Drug: Placebos
Drug: Methylprednisolone

First Posted Date: 2017-11-28

Last Posted Date: 2024-02-20

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 9

Registration Number: NCT03355482

Locations: 🇺🇸
Access Health, Las Vegas, Nevada, United States

Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy

Phase 4

Conditions: Systemic Lupus Erythematosus

Interventions: Biological: belimumab

First Posted Date: 2014-10-22

Last Posted Date: 2017-12-07

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 20

Registration Number: NCT02270970

Locations: 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Other: Placebo
Biological: Abatacept

First Posted Date: 2014-10-22

Last Posted Date: 2022-01-26

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 66

Registration Number: NCT02270957

Locations: 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

Not Applicable

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: extended release dipyridamole 200mg/aspirin 25mg
Drug: 81mg aspirin

First Posted Date: 2013-02-01

Last Posted Date: 2020-11-25

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 18

Registration Number: NCT01781611

Locations: 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States

Safety of Zostavax Vaccination in Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis
Varicella Zoster

Interventions: Drug: Zostavax (varicella zoster virus) vaccine

First Posted Date: 2012-01-10

Last Posted Date: 2020-03-06

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 20

Registration Number: NCT01506661

Locations: 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States

Zostavax in Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Zostavax vaccine

First Posted Date: 2011-11-18

Last Posted Date: 2013-09-17

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 20

Registration Number: NCT01474720

Locations: 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: certolizumab pegol

First Posted Date: 2010-10-01

Last Posted Date: 2017-12-07

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 20

Registration Number: NCT01213017

Locations: 🇺🇸
Arthritis and Rheumatic Disease Specialties, Aventura, Florida, United States
🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States

Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Group A SLE prospective study
Other: Blood drawing only Group C
Other: Group B SLE one blood donation

First Posted Date: 2009-10-01

Last Posted Date: 2014-10-20

Lead Sponsor: Oklahoma Medical Research Foundation

Target Recruit Count: 158

Registration Number: NCT00987831

Locations: 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
🇺🇸
Pfizer Inc, Collegeville, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy